Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently ...

Shares of Candel Therapeutics Inc. (CADL) surged over 9% on Friday morning, reaching their highest level in nearly a month ...

Fintel reports that on December 8, 2025, Stephens & Co. reiterated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Overweight recommendation. Analyst Price Forecast Suggests 256.43% Upside As ...

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

A clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion. Focused on the development of multimodal biological immunotherapies to help ...

A phase 3 prostate cancer trial of Candel Therapeutics' oncolytic virus has met its primary endpoint, sending the stock up more than 200%. The phase 3 hit was however offset by the failure of a ...

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

Candel priced its $80 million underwritten public offering of shares and pre-funded warrants. The company plans to use the funds from the public offering to advance its product candidates. Get ahead ...

Like many a biotech company in 2021, Candel Therapeutics filed to raise up to $100 million in its IPO. But unlike several of its peers, which outraised that initial figure by two- or even threefold, ...

NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...

Candel Therapeutics, Inc. has announced an underwritten public offering to raise $80 million through the sale of its common stock and pre-funded warrants. The company plans to use the proceeds to ...